You are here: Home: PCUTT1 | 2007: Management of High-Risk, Localized Disease - Select Publications

SELECT PUBLICATIONS

Aus G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU Int 2002;90(6):561-6. Abstract

D’Amico AV et al. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007;110(8):1723-8. Abstract

Gleave ME et al; Canadian Uro-Oncology Group. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 2001;166(2):500-6. Abstract

Klotz LH et al; Canadian Uro-Oncology Group. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170(3):791-4. Abstract

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8. Abstract

Schulman CC et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38(6):706-13. Abstract

Seidenfeld J et al. Competing risks for patients with localized prostate cancer. J Natl Cancer Inst 2007;99(20):1498-9. No abstract available

Selli C et al; PROSIT Study Group. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 2002;55(7):508-13. Abstract

Soloway MS et al; Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112-6. Abstract

 

 

 

Home